Fluzoparib
- Generic Name
- Fluzoparib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H16F4N6O2
- CAS Number
- 1358715-18-0
- Unique Ingredient Identifier
- TWF0ML1CK8
- Background
Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).
- Indication
⑴适用于既往经过二线及以上化疗的伴有胚系BRCA突变(gBRCAm)的铂敏感复发性卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。⑵适用于铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后的维持治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Clinical trial landscape for histone deacetylation inhibitors in breast cancer: a dawn in the darkness?
Clinical trials of HDAC inhibitors in BRCA are widespread, with Chidamide, Vorinostat, and Entinostat being the most studied. Most trials are in early phases, combining HDAC inhibitors with other treatments like hormone therapy, targeted therapy, and immunotherapy, reflecting the complexity of BRCA's molecular subtypes. Further research is needed to understand the mechanisms of HDAC inhibitor treatments in BRCA.
New evidence of the impact of the national drug price negotiation policy
The 2021 National Drug Price Negotiation (NDPN) policy in China significantly improved availability and utilization of anticancer drugs, with a notable decrease in cost, though regional disparities persist. The study highlights the policy's success in enhancing drug accessibility and affordability, yet calls for continuous monitoring to further improve drug availability.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath